Search results for "Evidence-based"

showing 10 items of 353 documents

Review and update on drugs related to the development of osteonecrosis of the jaw

2019

Conflict of interest Conclusions of the working group on “New drugs related to the de-velopment of osteonecrosis of the jaw”. Spanish Society of Cranio-mandibular Dysfunction and Orofacial Pain and Spanish Society of Oral Medicine SEDCYDO-SEMO joint International Meeting: 30th SEDCYDO annual meeting & 15th SEMO Congress. Bilbao (Spain); June, 2019. [EN] Background: Medication-related osteonecrosis of the jaw (MRONJ) is a rare, but serious adverse effect of cer-tain drugs, of which bisphosphonates are the most widely known. This pathology is also associated with other medications such as the biologic antiresorptive agent, denosumab and some antiangiogenics such as sunitinib, bevacizumab or a…

medicine.medical_specialtyBevacizumabReviewMRONJ03 medical and health sciencesantiresorptives0302 clinical medicinemedicineHumansIntensive care medicineAdverse effectGeneral DentistrybisphosphonatesAfliberceptBisphosphonate-associated osteonecrosis of the jawOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industrySunitinibOsteonecrosis030206 dentistryEvidence-based medicinemedicine.disease:CIENCIAS MÉDICAS [UNESCO]osteonecrosis of the jawantiangiogenicsDenosumabOtorhinolaryngologyPharmaceutical PreparationsUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawDenosumabbusinessOsteonecrosis of the jawmedicine.drug
researchProduct

Traditional Chinese medicine research in the post-genomic era: good practice, priorities, challenges and opportunities.

2012

Abstract Background and aims GP-TCM is the 1st EU-funded Coordination Action consortium dedicated to traditional Chinese medicine (TCM) research. This paper aims to summarise the objectives, structure and activities of the consortium and introduces the position of the consortium regarding good practice, priorities, challenges and opportunities in TCM research. Serving as the introductory paper for the GP-TCM Journal of Ethnopharmacology special issue, this paper describes the roadmap of this special issue and reports how the main outputs of the ten GP-TCM work packages are integrated, and have led to consortium-wide conclusions. Materials and methods Literature studies, opinion polls and di…

medicine.medical_specialtyBiomedical ResearchCollaborative networkMEDLINEAlternative medicineAcupuncture TherapyOmicsGuidelines as TopicGuidelines03 medical and health sciencesPharmacovigilance0302 clinical medicineTraditional Chinese medicineDrug Discoverymedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unionCooperative BehaviorMedicine Chinese Traditional030304 developmental biologyGrand Challengesmedia_commonGP-TCMPharmacology0303 health sciencesIntegrative MedicineEvidence-Based MedicineTraditional medicinebusiness.industrySystems BiologyAcupunctureEvidence-based medicineGenomics3. Good health030220 oncology & carcinogenesisEngineering ethicsIntersectoral CollaborationIntegrative medicineChinese herbal medicinebusinessDrugs Chinese HerbalPhytotherapyJournal of ethnopharmacology
researchProduct

Guidelines for the management of osteoporosis and fragility fractures

2018

The purpose of this document, a result of the harmonisation and revision of Guidelines published separately by the SIMFER, SIOMMMS/SIR, and SIOT associations, is to provide practical indications based on specific levels of evidence and various grades of recommendations, drawn from available literature, for the management of osteoporosis and for the diagnosis, prevention, and treatment of fragility fractures. These indications were discussed and formally approved by the delegates of the Italian Scientific Associations involved in the project (SIE, SIGG, SIMFER, SIMG, SIMI, SIOMMMS, SIR, and SIOT). The purpose of this document, a result of the harmonisation and revision of Guidelines publishe…

medicine.medical_specialtyBone densityOsteoporosis030204 cardiovascular system & hematologyEM - Original03 medical and health sciences0302 clinical medicineFragilityBone DensitymedicineSettore MED/33 - Malattie Apparato LocomotoreInternal MedicineHumans030212 general & internal medicineFractures; Osteoporosis; Therapy; Internal Medicine; Emergency Medicinebusiness.industryOsteoporosiEvidence-based medicinemedicine.diseaseFractures; Osteoporosis; TherapyFractureItalyFamily medicineEmergency MedicineOsteoporosisTherapybusinessFracturesOsteoporotic Fractures
researchProduct

Routine cardiac troponin assessment after percutaneous coronary intervention

2019

: Although the angiographic and procedural success of percutaneous coronary intervention (PCI) is now very high, some severe complications may still develop, including periprocedural myocardial infarction (MI). An accurate diagnosis of this condition is essential for guiding the clinical management, as these patients may need a tailored management. The current recommendations for diagnosing periprocedural myocardial infarction based on the fourth universal definition appear at first sight straightforward, but the clinical and prognostic significance of routine periprocedural cardiac troponin (cTn) assessment remains uncertain. The current scientific evidence suggests that the likelihood of …

medicine.medical_specialtyCardiac troponincardiaccardiac troponin percutaneous coronary interventionmedicine.medical_treatmentMyocardial Infarction030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicinePredictive Value of TestsRisk FactorsInternal medicinemedicineHumanscardiovascular diseases030212 general & internal medicineMyocardial infarctionEvidence-Based Medicinebiologybusiness.industryReproducibility of ResultsPercutaneous coronary interventionGeneral MedicineEvidence-based medicinemedicine.diseaseTroponinTroponinTreatment OutcomePredictive value of testsConventional PCIbiology.proteinCardiologyMyocardial infarction diagnosisCardiology and Cardiovascular MedicinebusinessBiomarkersJournal of Cardiovascular Medicine
researchProduct

A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin

2013

Ghrelin is a peptide hormone produced mainly in the stomach that has widespread tissue distribution and diverse hormonal, metabolic and cardiovascular activities. The circulating ghrelin concentration increases during fasting and decreases after food intake. Ghrelin secretion may thus be initiated by food intake and is possibly controlled by nutritional factors. Lean subjects have increased levels of circulating ghrelin compared with obese subjects. Recent reports show that low plasma ghrelin is associated with elevated fasting insulin levels, insulin resistance and type 2 diabetes mellitus. Factors involved in the regulation of ghrelin secretion have not yet been defined; however, it is as…

medicine.medical_specialtyCardiotonic AgentsHyperlipidemias030209 endocrinology & metabolismPeptide hormoneBiologyCardiovascular System03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicineDiabetes mellitusInsulin SecretionDrug DiscoverymedicineAnimalsHumansHypoglycemic AgentsInsulinAntiatherogenic agentHypolipidemic Agents030304 developmental biology2. Zero hungerPharmacology0303 health sciencesEvidence-Based Medicinedigestive oral and skin physiologyType 2 Diabetes MellitusLipid Metabolismmedicine.diseaseGhrelin3. Good healthEndocrinologyDiabetes Mellitus Type 2Cardiovascular DiseasesGastric MucosaHyperglycemiaGhrelinhormones hormone substitutes and hormone antagonistsGhrelin secretionHormoneCurrent Pharmaceutical Design
researchProduct

Is it really important for sick people to perform exercise?

2006

medicine.medical_specialtyChronic diseasebusiness.industryMEDLINEPhysical therapyReview Literature as TopicMedicinePhysical Therapy Sports Therapy and RehabilitationOrthopedics and Sports MedicineExercise therapyEvidence-based medicinebusinessQuality-adjusted life yearScandinavian Journal of Medicine and Science in Sports
researchProduct

Atherosclerosis, degenerative aortic stenosis and statins

2009

Aortic stenosis is the most common valvular heart disease among adult subjects in western countries The current treatment for aortic stenosis is aortic valve replacement. The possibility of a medical treatment that can slow the progression of aortic stenosis is very fascinating and statins have been tested to reduce the progression of degenerative aortic stenosis (DAS). The rationale for statin treatment in DAS has a deep pathophysiological substrate, in fact inflammation and lipid infiltration constitute the same histopathological pattern of both aortic stenosis and atherosclerosis and these two conditions have the same risk factors. Whether retrospective studies have shown some efficacy o…

medicine.medical_specialtyClinical BiochemistryInflammationlaw.inventionCoronary artery diseaseRandomized controlled trialAortic valve replacementlawInternal medicineDrug DiscoverymedicineAnimalsHumansPharmacologyEvidence-Based Medicinebusiness.industryvalvular heart diseaseRetrospective cohort studyAortic Valve Stenosismedicine.diseaseAtherosclerosisSettore MED/11 - Malattie Dell'Apparato Cardiovascolareatherosclerosis aortic stenosis statinStenosiscardiovascular systemCardiologyMolecular Medicinemedicine.symptomHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCalcification
researchProduct

Use of Expert Consensus to Improve Atherogenic Dyslipidemia Management

2013

Abstract Introduction and objectives Although atherogenic dyslipidemia is a recognized cardiovascular risk factor, it is often underassessed and thus undertreated and poorly controlled in clinical practice. The objective of this study was to reach a multidisciplinary consensus for the establishment of a set of clinical recommendations on atherogenic dyslipidemia to optimize its prevention, early detection, diagnostic evaluation, therapeutic approach, and follow-up. Methods After a review of the scientific evidence, a scientific committee formulated 87 recommendations related to atherogenic dyslipidemia, which were grouped into 5 subject areas: general concepts (10 items), impact and epidemi…

medicine.medical_specialtyConsensusDelphi TechniqueGuidelines as TopicScientific evidenceTherapeutic approachRisk FactorsMultidisciplinary approachEpidemiologymedicineHumansRisk factorDyslipidemiascomputer.programming_languageAtherogenic dyslipidemiaEvidence-Based Medicinebusiness.industryExpert consensusGeneral MedicineAtherosclerosisAtherogenic dyslipidemia Cardiovascular risk Consenso Consensus Delphi Dislipemia aterogénica HDL-C LDL-C Riesgo cardiovascular high-density lipoprotein cholesterol low-density lipoprotein cholesterolCardiovascular DiseasesFamily medicinePhysical therapybusinesscomputerDelphiRevista Española de Cardiología (English Edition)
researchProduct

OARSI–OMERACT definition of relevant radiological progression in hip/knee osteoarthritis

2009

Summary Background Joint space width (JSW) evaluated in millimeters on plain X-rays is the currently optimal recognized technique to evaluate osteoarthritis (OA) structural progression. Data obtained can be presented at the group level (e.g., mean±standard deviation of the changes). Such presentation makes difficult the interpretation of the clinical relevance of the reported results. Therefore, a presentation at the individual level (e.g., % progressors) seems more attractive but requires to determining a cut-off. Several methodologies have been proposed to define cut-offs in JSW: arbitrary chosen cut-off, cut-off based on the validity to predict a relevant end-point such as the requiremen…

medicine.medical_specialtyConsensusKnee JointRadiographyBiomedical EngineeringOsteoarthritisCutoffsArticleOsteoarthritis HipRheumatologyReference ValuesReliability studyOsteoarthritisMedicineHumansMedical physicsOrthopedics and Sports MedicineReliability (statistics)Clinical Trials as Topicbusiness.industryEvidence-based medicineOsteoarthritis Kneemedicine.diseaseClinical trialRadiographyRadiological weaponPhysical therapyDisease ProgressionFeasibility StudiesHip JointJoint space widthbusinessMedline databaseOsteoarthritis and Cartilage
researchProduct

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis.

2018

Background and purpose: Multiple sclerosis (MS) is a complex disease of the central nervous system. As new drugs are becoming available, knowledge on diagnosis and treatment must continuously evolve. There is therefore a need for a reference tool compiling current data on benefit and safety, to aid professionals in treatment decisions and use of resources across Europe. The European Committee of Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy of Neurology (EAN) have joined forces to meet this need. The objective was to develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS to guide healthcare professionals in…

medicine.medical_specialtyConsensusMultiple SclerosisdemyelinatingComplex diseasedisease-modifying therapies GRADE methodology guideline Multiple sclerosis Neurology Neurology (clinical)Outcome (game theory)Pharmacological treatmentImmunomodulation03 medical and health sciences0302 clinical medicineIntervention (counseling)GRADE methodologyAgency (sociology)Nominal group techniquemedicineImmunologic FactorsRelevance (law)Humans030212 general & internal medicineneurological disorderdisease-modifying therapiesIntensive care medicineSocieties MedicaldiseaseEvidence-Based Medicinebusiness.industryMultiple sclerosisdisease-modifying treatmentGuidelinemedicine.diseaseresearch methodEuropeNeurologymultiple sclerosiFamily medicinePractice Guidelines as TopicNeurology (clinical)businessguideline030217 neurology & neurosurgeryEuropean journal of neurology
researchProduct